AxoGen, Inc. (NASDAQ:AXGN – Free Report) – Analysts at Leerink Partnrs lowered their FY2028 EPS estimates for shares of AxoGen in a report released on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky now expects that the medical equipment provider will earn $0.12 per share for the year, down from their previous estimate of $0.13. The consensus estimate for AxoGen’s current full-year earnings is ($0.33) per share.
AxoGen (NASDAQ:AXGN – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.10. AxoGen had a negative return on equity of 17.30% and a negative net margin of 9.53%. The company had revenue of $47.91 million for the quarter, compared to analysts’ expectations of $43.27 million.
Check Out Our Latest Research Report on AXGN
AxoGen Stock Performance
NASDAQ AXGN opened at $13.24 on Friday. The business’s 50 day moving average price is $13.26 and its 200-day moving average price is $9.40. AxoGen has a fifty-two week low of $3.45 and a fifty-two week high of $15.23. The company has a market cap of $578.65 million, a P/E ratio of -26.48 and a beta of 1.13. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.32 and a current ratio of 3.51.
Hedge Funds Weigh In On AxoGen
Several institutional investors have recently made changes to their positions in the company. nVerses Capital LLC purchased a new stake in AxoGen in the third quarter worth about $56,000. Koss Olinger Consulting LLC purchased a new position in AxoGen during the 2nd quarter valued at about $75,000. Lazard Asset Management LLC raised its holdings in shares of AxoGen by 30.1% in the 1st quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock valued at $93,000 after purchasing an additional 2,671 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of AxoGen in the 2nd quarter worth approximately $125,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of AxoGen by 8.6% during the first quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock valued at $168,000 after purchasing an additional 1,651 shares in the last quarter. Hedge funds and other institutional investors own 80.29% of the company’s stock.
About AxoGen
AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
Featured Articles
- Five stocks we like better than AxoGen
- Compound Interest and Why It Matters When Investing
- Global Lithium Demand Soars: Top 3 Stocks Positioned to Gain
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Oil Prices Fall, Sector Pulls Back: Time to Buy this Stock?
- Do ETFs Pay Dividends? What You Need to Know
- AI Boom Fuels Demand for Dominion Energy Stock
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.